Antihypertensive Treatment With β‐Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events. Issue 12 (27th November 2017)

• Record Type: Journal Article
• Authors: Bang, Casper N.; Greve, Anders M.; Rossebø, Anne B.; Ray, Simon; Egstrup, Kenneth; Boman, Kurt; Nienaber, Christoph; Okin, Peter M.; Devereux, Richard B.; Wachtell, Kristian
• Is Part Of: Journal of the American Heart Association. Volume 6:Issue 12(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-11-27
• Subjects: aortic valve stenosis -- arrhythmia (heart rhythm disorders) -- atrial fibrillation -- β‐blocker -- high blood pressure -- hypertension; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.117.006709
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: Patients with aortic stenosis (AS) often have concomitant hypertension. Antihypertensive treatment with a β‐blocker (Bbl) is frequently avoided because of fear of depression of left ventricular function. However, it remains unclear whether antihypertensive treatment with a Bbl is associated with increased risk of cardiovascular events in patients with asymptomatic mild to moderate AS. Methods and Results: We did a post hoc analysis of 1873 asymptomatic patients with mild to moderate AS and preserved left ventricular ejection fraction in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study. Propensity‐matched Cox regression and competing risk analyses were used to assess risk ratios for all‐cause mortality, sudden cardiac death, and cardiovascular death. A total of 932 (50%) patients received Bbl at baseline. During a median follow‐up of 4.3±0.9 years, 545 underwent aortic valve replacement, and 205 died; of those, 101 were cardiovascular deaths, including 40 sudden cardiovascular deaths. In adjusted analyses, Bbl use was associated with lower risk of all‐cause mortality (hazard ratio 0.5, 95% confidence interval 0.3‐0.7, P <0.001), cardiovascular death (hazard ratio 0.4, 95% confidence interval 0.2‐0.7, P <0.001), and sudden cardiac death (hazard ratio 0.2, 95% confidence interval 0.1‐0.6, P =0.004). This was confirmed in competing risk analyses (all P <0.004). No interaction was detected with AS severity (all P >0.1). Conclusions: In post hoc analyses Bbl therapy did not increase the risk of all‐cause mortality, sudden cardiac death, or cardiovascular death in patients with asymptomatic mild to moderate AS. A prospective study may be warranted to determine if Bbl therapy is in fact beneficial. Clinical Trial Registration: URL:http://www.clinicaltrials.gov . Unique identifier: NCT00092677.